HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 318.12% from the company’s previous close. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ FY2030 earnings at ($2.61) EPS.

FDMT has been the subject of several other reports. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Barclays started coverage on 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada lifted their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Chardan Capital reissued a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $32.71.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $8.61 on Friday. The business has a fifty day moving average of $8.75 and a 200 day moving average of $9.12. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $12.34. The firm has a market capitalization of $439.54 million, a price-to-earnings ratio of -3.56 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The company had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. As a group, equities research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $46,000. Millennium Management LLC raised its holdings in shares of 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. American Century Companies Inc. boosted its position in shares of 4D Molecular Therapeutics by 11.5% during the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after acquiring an additional 5,026 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $292,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

More 4D Molecular Therapeutics News

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.